Chlamydia trachomatis is a major pathogen causing trachoma, the leading infectious cause of blindness affecting 500 million people worldwide. This editorial examines immunity to C. trachomatis through research conducted in the Gambian village of Jali, where trachoma is endemic. Early whole-organism vaccines provided poor protection and sometimes increased disease severity. The authors investigated the role of humoral and cellular immunity in ocular infection using tear samples and peripheral blood from the Jali population. Surprisingly, IgG antibodies were associated with increased disease incidence and duration, suggesting they may enhance rather than protect against infection. IgA antibodies showed protective trends but were not statistically significant. Despite high local antibody levels and minimal genetic variation in the major outer-membrane protein (MOMP), the organism persisted without apparent escape mutants, indicating antibodies play a limited role in protection. In contrast, cell-mediated immune responses were significantly reduced in subjects with persistent disease or scarring trachoma compared to controls. The findings suggest that protective immunity depends primarily on T-helper 1 (Th-1) cell-mediated responses rather than antibody responses, with interferon-gamma playing a key anti-chlamydial role. These observations have important implications for developing an effective C. trachomatis vaccine.

Key findings

• IgG antibodies to C. trachomatis were associated with increased disease incidence and duration, suggesting they enhance rather than prevent infection
• The organism persists in the population without significant escape mutants despite high local antibody levels, indicating antibodies provide minimal protective immunity
• Subjects with persistent or scarring trachoma had significantly reduced cell-mediated immune responses to chlamydial antigens compared to controls
• Protective immunity appears dependent on Th-1 type cell-mediated responses mediated by interferon-gamma rather than antibody-based immunity